EDEM2

EDEM2 is an ER-luminal factor that initiates glycoprotein ER-associated degradation (ERAD) by catalyzing the first mannose-trimming step, converting Man9GlcNAc2 to the Man8GlcNAc2 isomer B that commits misfolded glycoproteins to disposal (PMID:25092655). Its alpha-1,2-mannosidase activity is conditional: it acts efficiently on denatured glycoproteins rather than free oligosaccharides or folded substrates, coupling catalysis to the unfolded state of its targets (PMID:30374462). This activity is contingent on a stable disulfide bond between EDEM2 C558 and C692 in the Trx5 (CXXC) domain of the oxidoreductase TXNDC11; the covalent EDEM2–TXNDC11 complex reconstitutes Man9-to-Man8 trimming in vitro and is required for downstream gpERAD in cells (PMID:30374462, PMID:32065582). Beyond glycan recognition, EDEM2 engages substrates through hydrophobic polypeptide determinants independent of glycosylation, binding misfolded and non-glycosylated substrates and exposed hydrophobic regions (PMID:24910992, PMID:25655076), and it interfaces with the ER quality-control machinery including calnexin and SEL1L to channel substrates toward degradation (PMID:24910992). Outside its canonical ERAD role, EDEM2 is transcriptionally induced by XBP1s in cardiomyocytes, where it promotes SEC23A-mediated translocation of the lipase ATGL to restrain lipid droplet accumulation and regulate cardiac lipid homeostasis (PMID:40130322).

1. 2004 Medium

   Established EDEM2 as an ER-resident ERAD factor before any enzymatic role was known, answering whether the orphan ORF participated in misfolded-glycoprotein disposal.

   Evidence ER localization, co-IP with misfolded alpha1-antitrypsin, and overexpression degradation assay in HEK293, with a negative in vitro mannosidase result

   PMID:15537790

   Open questions at the time

   • No enzymatic activity detected, leaving its mechanism of action undefined
   • Single substrate (alpha1-antitrypsin) and single lab
   • Did not distinguish direct catalysis from adaptor function
2. 2014 High

   Defined EDEM2's specific catalytic position in the ERAD mannose-trimming cascade, resolving how it differs from EDEM1 and EDEM3.

   Evidence TALEN knockout in human cells with glycan structure analysis and epistasis across EDEM1/2/3 knockouts

   PMID:25092655

   Open questions at the time

   • Did not demonstrate direct enzymatic activity in vitro at this stage
   • Cofactor requirement for the activity unknown
   • Did not address non-glycan substrate recognition
3. 2014 Medium

   Showed EDEM2 recognizes substrates beyond their glycans and physically links to core ER quality-control machinery, broadening its role from pure mannosidase to substrate-channeling factor.

   Evidence siRNA knockdown plus co-IP with non-glycosylated SHH, calnexin, and SEL1L; ricin A-chain retrotranslocation assays

   PMID:24200403 PMID:24910992

   Open questions at the time

   • Molecular basis of polypeptide recognition not yet defined
   • Direct vs. indirect interaction with calnexin/SEL1L not resolved
   • Single lab per substrate
4. 2015 Medium

   Identified hydrophobicity of substrate determinants as the basis for glycosylation-independent recognition, explaining how EDEM2 engages misfolded polypeptide regions.

   Evidence Hydrophobicity-modulating mutagenesis of ricin and BACE457 with co-IP in human cells

   PMID:25655076

   Open questions at the time

   • No structural map of the polypeptide-binding surface
   • Relationship between hydrophobic binding and mannosidase catalysis unclear
   • Single lab
5. 2018 High

   Demonstrated that EDEM2's mannosidase activity is gated by substrate unfolding and enhanced by an oxidoreductase partner, reconciling earlier negative in vitro activity results.

   Evidence In vitro mannosidase assays comparing free N-glycans, folded and denatured glycoproteins, plus co-IP identifying TXNDC11

   PMID:30374462

   Open questions at the time

   • Did not define the chemical nature of the EDEM2-TXNDC11 link
   • Mechanism by which unfolding enhances activity not resolved
6. 2020 High

   Pinpointed the covalent EDEM2-TXNDC11 disulfide as essential for catalysis and reconstituted the first clear in vitro EDEM-family mannosidase activity, settling how EDEM2 becomes enzymatically competent.

   Evidence CRISPR KO, site-directed mutagenesis of EDEM2 C558 and TXNDC11 C692, disulfide mapping, complex purification, and in vitro Man9-to-Man8 trimming with MS glycan analysis in HCT116

   PMID:32065582

   Open questions at the time

   • No high-resolution structure of the complex
   • How TXNDC11 redox state modulates activity not defined
   • Connection between disulfide-driven catalysis and hydrophobic substrate recognition unaddressed
7. 2021 Medium

   Mapped the EDEM2 interactome and endogenous substrate landscape, extending its role beyond model substrates to ER quality-control networks and disease-relevant targets.

   Evidence Affinity proteomics, sucrose density fractionation, deglycoproteomics, and SILAC pulse proteomics in melanoma cells with biochemical validation

   PMID:34332121

   Open questions at the time

   • Substrate candidates (integrin alpha-1, protocadherin 2) inferred from correlation, not direct degradation kinetics
   • Functional roles of novel interactors not characterized
   • Single cell-type context
8. 2025 Medium

   Revealed a non-canonical EDEM2 function in cardiac lipid homeostasis under XBP1s control, distinguishing its ERAD role from a lipid-regulatory role.

   Evidence AAV9 loss/gain-of-function in mice, siRNA in rat and hiPSC cardiomyocytes, luciferase reporter for XBP1s regulation, proteomics, lipidomics, and EM

   PMID:40130322

   Open questions at the time

   • Mechanistic link between EDEM2 and SEC23A-mediated ATGL translocation not resolved at molecular level
   • Whether mannosidase activity is required for the lipid role is untested
   • Cardiomyocyte-specific; generality unknown

• How EDEM2's two recognition modes — glycan trimming and hydrophobicity-based polypeptide binding — are structurally integrated, and whether the lipid-regulatory function depends on its catalytic activity, remain open.
• No crystal/cryo-EM structure of the EDEM2-TXNDC11 complex with substrate
• Mechanistic coupling of catalysis to ERAD channeling unresolved
• Catalytic dependence of the ATGL/lipid pathway untested